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A gastric outlet obstruction (GOO) is characterized by postprandial vomiting and abdominal pain, which occur due to the mechanical obstruction of the gastric discharge. The causes of GOO in childhood include stenosis after corrosive substance ingestion or a primary peptic ulcer (PU), non-steroidal antiinflammatory drug (NSAID) induced strictures, congenital causes (webs, duplication cysts, ectopic pancreas, etc.), inflammatory causes (pancreatitis, cholecystitis, Crohn's disease), polyps/tumors, and other rare conditions (bezoars, cytomegalovirus infection, volvulus). 1 Surgery has been the treatment mainstay in the congenital and many of the acquired conditions, but over the last few decades, endoscopic balloon dilatation (EBD) has been used in selected cases, depending on the patient characteristics and the etiology of the GOO. In this article, we present a patient with a NSAID-related pyloric obstruction, who was treated successfully with an EBD.
Case Report
A 7-year-old boy was referred to our hospital for upper gastrointestinal (UGI) bleeding. He had an upper respiratory tract infection for one week and was being treated with ibuprofen and acetylsalicylic acid (ASA) during that time. The patient was admitted to the clinic with hematemesis and melena over the previous 2 days. The physical examination revealed a body weight in the 25-50 th percentile, height in the 50 th percentile, pale appearance, increased bowel sounds, and tachycardia. The complete blood count showed a decreased hemoglobin level (8.2 g/dl), white blood cell (WBC) count of 11,500 cells/μL (N: 4,200-10,600; 55% neutrophils and 45% lymphocytes) and a platelet count of 372,000/μL (N: 140,000-400,000). No evidence of atypia was observed in the peripheral blood smear. The biochemical and coagulation tests were normal, with the exception of the C-reactive protein, which was high (75 mg/L, N: 0.0-0.8).
sucralfate were started for the UGI tract bleeding. On the 2 nd day, a UGI endoscopy showed extensive ulceration at the pyloric canal but no active bleeding ( Fig. 1 ). In the histopathological examination, the test for Helicobacter pylori was negative, and the treatment was continued with a proton pump inhibitor (PPI) and sucralfate. On the fourth day of admission, oral feeding was started and the blood gastrin level of the patient was observed within normal range. At the end of the 7 th day of follow-up, the patient had begun vomiting, but the direct abdominal X-ray results were normal and there was partial pyloric passage evident on the UGI contrast study. The amylase and lipase levels were normal during this period.
In terms of a differential diagnosis, celiac serology was obtained; the perinuclear antineutrophil cytoplasmic antibody (p-ANCA) test was negative and the immunoglobulins were normal. Since this patient exhibited concomitant fever and vomiting, a magnetic resonance investigation was done to exclude an intracranial infection. Although an arachnoid cyst was detected, it was not considered to be associated with the vomiting. In addition, superior mesenteric artery syndrome was ruled out after a normal abdominal computed tomography angiography. On the 20 th day, approximately 1,000 ml of gastric fluid was aspirated during a UGI endoscopy, and the pyloric output was observed as stenotic, edematous, and erythematous ( Fig. 2) . These findings suggested a GOO secondary to the PU in the patient. Therefore, an EBD was performed using balloons with 8-mm and 12-mm outer diameters, respectively (Fig. 3) . After four interventions, which were made at intervals of one week, the pyloric canal diameter reached 8 mm, with no meal residue at the following control endoscopy. The antacid and sucralfate treatments were continued, and the patient was followed up on an outpatient basis.
Twenty days later, it was observed that the patient could not tolerate eating solid foods. An endoscopy was performed, showing that the pyloric canal had an opening of 3 mm. Therefore, a total of 4 additional EBD sessions were performed at 3-4 week intervals. Once a pyloric canal diameter of approximately 8-9 mm was achieved, the patient was followed up weekly and questioned about his symptoms ( Fig. 4 ). After 2 months of follow-up, the patient had gained weight and showed no food intolerance. The PPI treatment was continued, and at one-year follow-up, the symptoms had not recurred.
Written consent for publication of this case report was obtained from the parents of the patient.
Discussion
In this case report, we have presented a pediatric patient with a GOO due to a pyloric PU, which was successfully managed with an EBD. The most common causes of pediatric GOOs are strictures after a PU or corrosive ingestion, iatrogenic causes (secondary to surgery), idiopathic hypertrophic pyloric stenosis, congenital causes, inflammatory causes, polyps/tumors, and the other rare conditions. 1 Among these, idiopathic hypertrophic pyloric stenosis and PUs remain the most common causes of GOOs in children. [2] [3] [4] In addition, ASA and NSAIDs are known to be associated with GOOs after gastrointestinal ulcers. 5 In pediatric practice, these drugs are often used in patients as antipyretics, but side effects have been reported. In a study of 51 patients in Italy regarding NSAID use, the rate of associated pain was 56.9%, PUs was 13.7%, hematemesis was 33.3%, and erosive lesions was 62%. 6 In addition to its direct effects, NSAIDs can cause pyloric edema by decreasing the prostaglandin E2 levels and increasing the gastric secretions by increasing the histamine levels indirectly.
Through these effects, the mucosal absorption and gastric motility diminish. Although the altered motility and edema can be responsible for the GOO at the beginning, subsequently occurring inflammation results in later fibrosis. 7 A GOO can be treated by either surgical or endoscopic methods. The most preferred interventions include a pyloric endoscopic dilatation, simultaneous dilatation with a steroid injection, surgical pyloroplasty, gastroduodenostomy, and gastrojejunostomy with or without the excision of the involved segment. 8 In the treatment of an acquired GOO, the development of endoscopy has become an important option, which also protects the patient from the possible complications of surgery. 9 However, there have been few reports about stricture development after NSAID intake and subsequent treatment with dilatation. The largest series on the successful management of an NSAID-induced pyloroduodenal obstruction using an EBD is from India, in which only one of 10 adult patients required surgery due to endoscopic therapy failure. 10 Moreover, the literature related to the EBD management of pediatric NSAID-related GOOs is scant, and we found only one case report regarding the use of an EBD to treat an NSAID-related GOO successfully in a child. 11 However, there were also cases of a dilatation after a myotomy, especially for obstructions after corrosive substance ingestion. 4 Ozokutan et al. 12 reported that the mean duration for the development of a GOO after corrosive ingestion was 21-45 days. In addition, the development of a GOO due to PU-associated fibrosis and stricture development was reported as 2-6 weeks on average. 13 The development of fibrosis and a stricture increases gradually during the healing period of the ulcer, and although the ulcer does heal, the subsequent stricture causes the obstruction. We also observed this clinical course in our patient, in which the symptoms began on the 7 th day of admission, and the vomiting increased significantly until the 14 th day. A GOO was considered due to the resistant nonbilious vomiting of nondigested foods at the follow-up. The normal passage of the contrast material in the UGI contrast study on the 7 th day and the worsening symptoms showed that complete obstruction developed on the 14 th day. In light of these findings, we suggest performing a control endoscopy at a mean of two weeks or in the suspicion of GOO, especially for ulcers in the pyloric canal or nearby. Our patient underwent a total of 8 EBD sessions at periodic intervals over 5 months, and we did not find any evidence of perforation during the dilatation of the fibrotic segment of the pylorus. Only a small amount of bleeding was observed during the procedure. Moreover, there was no recurrent stenosis in our case at the one-year follow-up.
In conclusion, we believe that the careful observation of UGI symptoms is necessary when NSAIDs or ASA are used in pediatric patients. In such cases, a GOO should be considered in patients with resistant vomiting after UGI bleeding. We suggest using an EBD as a first choice in NSAID-related GOO cases in pediatric patients, with the consensus of pediatric surgery.
